Phase 1 clinical trials (NCT03207867, NCT03549000) testing the A2A adenosine receptor inhibitor taminadenant (NIR178) with anti-PD-1 spartalizumab and/or anti-CD73 fully human antibody NZV930 were accruing patients with pancreatic cancer and many other tumor types, but no data have yet been reported. This evidence concerns the gene PDCD1 and neoplasm.